Key result
Endovascular thrombectomy did not improve 90-day mRS 0-1 vs best medical treatment in DMVO stroke RCTs and increased sICH.
Why the study?
Does endovascular thrombectomy combined with best medical treatment improve 90-day excellent functional outcome (mRS 0-1) compared to best medical treatment alone in patients with distal medium vessel occlusion ischemic stroke?
Meta-Analysis (n=12,381)
Does endovascular thrombectomy combined with best medical treatment improve 90-day excellent functional outcome (mRS 0-1) compared to best medical treatment alone in patients with distal medium vessel occlusion ischemic stroke?
Answers are grounded in this paper and cite their sources.
Endovascular thrombectomy does not significantly improve 90-day functional outcomes in the overall distal medium vessel occlusion stroke population compared to best medical treatment alone, while significantly increasing the risk of symptomatic intracranial hemorrhage.
INTRODUCTION: Endovascular thrombectomy (EVT) is currently widely recommended for patients with large vessel occlusion stroke. However, evidence regarding its safety and efficacy in patients with distal medium vessel occlusion (DMVO) remains insufficient. Additionally, the effects of EVT in DMVO patients with varying degrees of severity are not well defined. METHODS: A systematic search was conducted across medical and biological databases since their inception to identify randomized controlled trials (RCTs) and observational studies comparing EVT with best medical treatment (BMT) in patients with DMVO ischemic stroke. Patients were stratified into three groups based on National Institutes of Health Stroke Scale (NIHSS) scores: mild stroke group (<6), moderate-to-severe stroke group (≥6), and NIHSS-unreported group (no clear score available). Additionally, patients were divided into three groups according to the occlusion site of the stroke: middle cerebral artery (MCA) group, posterior cerebral artery (PCA) group, and anterior cerebral artery group. The primary efficacy outcome was excellent outcome, defined as a 90-day modified Rankin Scale (mRS) score of 0-1. Secondary outcomes included 90-day functional independence (mRS 0-2), 90-day mortality, and symptomatic intracranial hemorrhage (sICH). RESULTS: Three RCTs (n = 1,233) and 39 observational studies (n = 11,148) were included. In RCTs, there was no statistically significant difference between EVT combined with BMT and BMT alone in terms of mRS 0-1 (RR 0.95, 95% CI 0.82-1.10, p = 0.46) and mRS 0-2 (RR 0.92, 95% CI 0.80-1.06, p = 0.27), and the mortality rates were also similar between the two groups (OR 1.23, 95% CI 0.76-1.99, p = 0.21). However, EVT significantly increased the risk of sICH (OR 2.38, 95% CI 1.35-4.20, p = 0.003). In the observational study cohort, there were no significant differences between EVT and BMT in terms of mRS 0-1 (RR 1.03, 95% CI 0.93-1.14, p = 0.56), mRS 0-2 (RR 1.01, 95% CI 0.94-1.08, p = 0.80), and mortality (OR 1.10, 95% CI 0.89-1.36, p = 0.37), while the risk of sICH remained significantly higher in the EVT group (OR 1.69, 95% CI 1.14-2.50, p = 0.008). Subgroup analyses from observational studies suggested potential baseline NIHSS stratification differences in treatment effects. In the primary NIHSS ≥6 subgroup analysis, EVT did not show a statistically significant difference compared with BMT for mRS 0-1 (RR 1.10, 95% CI 0.93-1.30, p = 0.28) or mRS 0-2 (RR 1.06, 95% CI 0.94-1.19, p = 0.34). In a sensitivity analysis excluding studies contributing to heterogeneity, a potential signal for benefit emerged (mRS 0-1: RR 1.18, 95% CI 1.01-1.37, p = 0.04), though this should be interpreted cautiously as a secondary exploratory finding. Conversely, in patients with mild symptoms and NIHSS <6, BMT alone may be non-inferior (RR 0.91, 95% CI 0.82-1.00, p = 0.05). These subgroup observations are hypothesis-generating and require confirmation in prospective trials. CONCLUSION: Based on RCT evidence, EVT does not significantly improve functional outcomes in the overall DMVO population but increases the risk of sICH. Exploratory subgroup analyses from observational studies suggest a potential gradient effect whereby EVT may be associated with better functional outcomes in patients with more severe stroke (NIHSS ≥6) and more proximal occlusions (MCA-M2, PCA-P1), though these findings are hypothesis-generating and require validation in adequately powered RCTs. For patients with NIHSS <6 or more distal occlusions, BMT alone may provide equivalent or better outcomes.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) conducted a meta-analysis in Distal medium vessel occlusion (DMVO) ischemic stroke (n=12,381). Endovascular thrombectomy (EVT) vs. Best medical treatment (BMT) was evaluated on Excellent outcome, defined as a 90-day modified Rankin Scale (mRS) score of 0-1 (RR 0.95, 95% CI 0.82-1.10, p=0.46). Endovascular thrombectomy did not improve 90-day mRS 0-1 vs best medical treatment in DMVO stroke RCTs and increased sICH.
Synapse has enriched 10 related papers. Consider them for comparative context: